OPK

OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market.

OPKO Health, Inc. (OPK) Q2 2026 Earnings Call Transcript

MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today reports business highlights and financial results for the second quarter ended June 30, 2026. Highlights from the second quarter of 2026 and recent weeks included the following: ModeX presented data on multispecific antibody targeted in vivo CAR T cell programs at the American Society of Gene + Cell Therapy (ASGCT) Annual Meeting, with plans to enter Phase 1 studies later this year or in early 2027.

OPKO Health's growth outlook rests on RAYALDEE, BioReference gains and partnerships, though losses and pipeline risks persist.

MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that it will report operating and financial results for the second-quarter 2026 on Monday, July 27, 2026. OPKO's senior management will host a conference call and webcast at 4:30 p.m. ET to provide a business update, discuss results and financial guidance.

MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) OPKO Biologics, an OPKO Health company, presented preclinical data for OPK8801001 at ENDO 2026, the Endocrine Society's annual meeting. The poster, “Production and Characterization of OPK8801001, a Novel Long-Acting hGH Receptor Antagonist for the Treatment of Acromegaly,” available here, was presented by Moran Golan, Ph.D., Director of Preclinical & Clinical Pharmacology at OPKO Biologics.

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?

OPKO Health leans on RAYALDEE and key partnerships, such as BioReference and 4Kscore, as it ramps toward mid-2026 diagnostics breakeven.

Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models  Data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting WESTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), will announce preclinical data demonstrating the in vivo generation of CAR-T cells and deep systemic B-cell depletion achieved with its MDX3001 candidate in animal models.

MIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) today announced that its subsidiary EirGen Pharma Limited (EirGen) has entered into an amendment to its agreement with Nicoya Therapeutics (Macau) Limited, an affiliate of Nicoya Therapeutics (Nicoya), which grants OPKO an equity stake in Nicoya and reinforces Nicoya's commitment to commercialize RAYALDEE® in Greater China. RAYALDEE is approved in Macau, and the companies expect regulatory approvals in China and related territories in 2027.